MB-105 CAR-T Therapy: Advancing Precision Treatment for CD5+ T-Cell Lymphoma

ONCOLife presents an exclusive interview with Sarah Hein, CEO and Co-Founder of March Biosciences. In this session, we explore groundbreaking clinical advancements in the field of CAR-T therapies, specifically focusing on MB-105, a novel CD5-targeted treatment currently in Phase 2 clinical trials for relapsed or refractory CD5-positive T-cell lymphoma. You can also follow this interview on LinkedIn using this link:>>>

Sarah Hein shares detailed insights into the unique mechanism of action behind MB-105, highlights key findings from earlier clinical phases, and addresses specific challenges and innovative solutions in treating T cell malignancies. We also explore the broader potential applications of MB-105 for other CD5-positive cancers and discuss March Biosciences' strategic vision, upcoming milestones, and international expansion efforts.

Some of the main topics in this interview include:

• To begin, could you provide a detailed overview of the mechanism of action of MB-105, and explain how it specifically addresses challenges associated with CD5-targeted CAR T-cell therapies?
• MB-105 has shown promising Phase 1 results in relapsed or refractory CD5+ T-cell lymphoma. Could you elaborate on the key findings from Phase 1 that encouraged progression into Phase 2?
• Given the unique CAR design of MB-105, how exactly does this approach selectively target malignant CD5-positive cells while preserving normal T-cell function?
• MB-105 received FDA orphan drug designation. How does this designation impact your clinical development strategy and timeline?
• Besides T-cell lymphoma, MB-105 is also under consideration for other CD5-positive cancers. Could you share insights into these additional therapeutic targets and any ongoing or planned studies?
• Given the challenges of treating T-cell malignancies, how do you foresee the therapeutic landscape evolving, and where does March Biosciences intend to position MB-105 within this context?